Access
Email Verification
Agenda 2024
DAY 1: WEDNESDAY, OCTOBER 9, 2024
0830 - 0930 REGISTRATION AND MORNING REFRESHMENTS
0930 - 0940 OPENING ADDRESS
0940 - 1005 ANTIMICROBIAL RESISTANCE MANUFACTURING CERTIFICATION SCHEME
- Overview of antimicrobial resistance sources and impacts on environments
- Role of the 2022 Antibiotic Manufacturing Standard in managing AMR risks
- Description of the certification process introduced by BSI in June 2023
- Benefits of third-party evaluation in antibiotic manufacturing transparency
Lisa Lowe
BSI
BSI
1005 - 1010 Q&A SESSION ON THE CERTIFICATION PROCESS IN ANTIBIOTIC MANUFACTURING
1010 - 1030 SPEED NETWORKING SESSION
- Exchange business cards and get connected in short one-to-one meetings
- Start the conversation to arrange a more formal meeting later on in the conference
- Share your professional background and discuss your biggest business issues – don't forget your business cards!
Conference Host
1030 - 1100 MORNING COFFEE BREAK IN THE EXHIBIT AREA
1100 - 1125 NOVEL ADVANCES IN DRUG-RESISTANT TB FOR A SHORTER, UNIVERSAL REGIMEN
- WHO recommendations of testing BPaL from June 2020
- Trials to global implementation of BPaL/M regimen by 2024
- Collaborative efforts towards a safer, universal TB treatment
Salah Foraida
TB Alliance
TB Alliance
1125 - 1130 Q&A SESSION ON TREATING DRUG-RESISTANT TB GLOBALLY
1130 - 1155 PHASE 2B STUDY FOR SAFETY AND EFFICACY OF BACTERIOPHAGE TP-102 IN DIABETIC FOOT INFECTION
- Results from Phase 2b clinical trials using bacteriophages for diabetic foot infections
- Exploring future directions and next steps in bacteriophage therapy for clinical use
- Challenges and successes in phage therapy and regulatory variations across regions
Sofia Corte-Real
TechnoPhage
TechnoPhage
1155 - 1200 Q&A SESSION ON EVALUATING BACTERIOPHAGE TP-102 FOR DIABETIC FOOT INFECTIONS
1200 - 1330 NETWORKING LUNCH AND VISITING THE GLOBAL AMR SUMMIT EXHIBITION
1330 - 1355 INSTRUMENT-FREE MOLECULAR DIAGNOSTICS FOR HOME APPLICATIONS
- Understand the decentralization strategy of diagnostics lab equipment to Home and Point-of-Care
- Introducing low-cost home diagnostics test to determine if it is a virus or bacteria infection
- Learn how to target the right antibiotic by using rapid diagnostics with molecular accuracy
Mohamed Azize
Analog Devices, Inc.
Analog Devices, Inc.
1355 - 1400 Q&A SESSION ON THE MOLECULAR LEVEL DIAGNOSTICS INSIGHTS FOR HOME AND POC
1400 - 1425 AI AND DATABASE MINING DELIVERING NEW ANTIMICROBIALS FOR WHO PATHOGENS
- Amprologix unveils pipeline of potent bacteriocins effective against key WHO pathogens
- Single dose efficacy demonstrated in animal models for major Gram-positive infections
- New antimicrobials for under $50m showcase potential to revolutionize the antibiotic market
- Over 200 candidates identified through novel mining, with the top 20 set for detailed study
Mathew Upton
Amprologix
Amprologix
1425 - 1430 Q&A SESSION ON AI'S ROLE IN ADVANCING ANTIMICROBIAL DEVELOPMENT
1430 - 1500 AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
1500 - 1525 “TROJAN HORSE” TECH FOR BROAD-SPECTRUM ANTIVIRALS
- NanoViricides has developed a novel polymeric micelle technology platform
- Effective in treating multiple viruses including coronaviruses and influenza
- Host-mimetic approach ensures viruses cannot evade treatment over time
- Technology would allow novel drug design and delivery to overcome AMR
Anil Diwan
NanoViricides
NanoViricides
1525 - 1530 Q&A SESSION ON BROAD-SPECTRUM ANTIVIRALS FOR MULTIPLE VIRUS
1530 - 1555 THE IMPORTANCE OF EARLY DETECTION: MY SEPSIS STORY
- Preventing antibiotic misuse through timely diagnosis
- Early recognition of carriers to enhance infection control
- Highlighting the criticality of AMR awareness and swift action
Jean Mwale
Miracles of Hope
Miracles of Hope
1555 - 1600 Q&A SESSION ON EARLY SEPSIS DETECTION STRATEGIES
1600 - 1625 COMBATING AMR THROUGH GLOBAL SURVEILLANCE AND STEWARDSHIP PROGRAMS
- Exploring the role of the Fleming Fund in enhancing global AMR surveillance
- Training initiatives for AMC software and antimicrobial stewardship programs
- Strengthening research and clinical engagement to manage antimicrobial use
Iftikhar Ahmad
DAI Fleming Fund
DAI Fleming Fund
1625 - 1630 Q&A SESSION ON GLOBAL AMR SURVEILLANCE STRATEGIES
1630 - 1730 NETWORKING DRINKS RECEPTION
Key topics for 2024:
- The future of drug development and vaccines to combat infections
Understanding the mechanisms and drivers of antimicrobial resistance and fighting antimicrobial resistance through novel antimicrobials and vaccines. - New developments in protein folding to curb antimicrobial resistance
Explore more about the omics of antimicrobial resistance and disrupting extracytoplasmic protein folding as molecular tools to fight antimicrobial resistance. - Latest research in antimicrobial photodynamic therapy as a molecular tool
Assessing the advances in photodynamic antimicrobial chemotherapy by conjugating biomaterials with photosensitizers as a molecular tool for antimicrobial resistance. - The role of AI in the design and development of next-generation antimicrobial
Looking at the role of artificial intelligence in advancing the design and discovery of novel artificial antimicrobials. - Advances in antimicrobial peptides and the development of novel antibiotics
Achieve a deeper understanding of drug repurposing in developing novel antimicrobials, antimicrobial peptides, and quorum-sensing inhibitors as future strategies in antibacterial agent design. - Global surveillance programs and stewardship platforms to control AMR
Learn how surveillance programs and stewardship platforms can drive change in AMR and the importance of collaboration with politicians and policymakers to control AMR.
Sponsorship Opportunities
Join us as a sponsor for this IQ International conference! Reach your target audience, limit competitor influence at the conference and become a keynote speaker, while sharing your company's solutions for this industry.
- Get registration discounts
- Enhance your brand awareness
- Additional marketing opportunities